Parkinson ‘s disease

Novartis Takes Another Shot at Alpha-Synuclein With $2.2B Arrowhead CNS Deal

1 week ago talkbio0Tagged alpha-Synuclein, ARO-SNCA, Arrowhead Pharmaceuticals, biotech partnerships, Gene Silencing, Nerve Degeneration, Novartis, Parkinson 's disease, RNA Interference, TRiM platform

Novartis; Arrowhead Pharmaceuticals; alpha-synuclein; Parkinson’s disease; RNA interference (RNAi); gene silencing; ARO-SNCA; TRiM platform; neurodegeneration; biotech partnerships

Roche Advances Prasinezumab Into Phase III Trials for Parkinson’s Despite Mixed Phase II Results

3 months ago talkbio0Tagged alpha-synuclein antibody, Biological Markers, Clinical Trials, disease-modifying treatment, PADOVA study, Parkinson 's disease, Pasadena, Phase 3 Clinical Trials, Prasinezumab, Prothena, Roche (company)

Roche; prasinezumab; Parkinson’s disease; Phase III trial; clinical trials; alpha-synuclein antibody; Prothena; PADOVA study; PASADENA study; biomarker; disease-modifying treatment

Forging the Future of Cell Therapy: Bayer and BlueRock’s Unique Journey

3 months ago talkbio0Tagged Bayer, bemdaneprocel, biotech partnerships, BlueRock Therapeutics, Cell Therapy, Identifier, Parkinson 's disease, Phase 3 trials, Regenerative Medicine, RMAT

cell therapy; Bayer; BlueRock Therapeutics; Parkinson’s disease; bemdaneprocel; biotech partnerships; RMAT designation; Phase 3 trials; regenerative medicine

MeiraGTx and Hologen AI Form $430M Collaboration to Advance Parkinson’s Gene Therapy

6 months ago talkbio0Tagged Artificial Intelligence, Biotechnology, Clinical Trials, gene therapy, Parkinson 's disease

gene therapy, Parkinson’s disease, artificial intelligence, clinical trials, biotechnology partnership

FDA Approves Onapgo: Breakthrough Infusion Device for Advanced Parkinson’s Disease

7 months ago talkbio0Tagged apomorphine hydrochloride, Approved, Infusion procedures, motor fluctuations, Onapgo, Parkinson 's disease, subcutaneous, Supernus, United States Food and Drug Administration

Onapgo, apomorphine hydrochloride, Parkinson’s disease, subcutaneous infusion, motor fluctuations, FDA approval, Supernus Pharmaceuticals

Inhibikase Halts Parkinson’s Drug Development After Phase II Failure, Shifts Focus to Pulmonary Arterial Hypertension

7 months ago talkbio0Tagged Clinical Failure, Drug Development, IkT-001Pro, Inhibikase, Parkinson 's disease, Phase 2 Clinical Trials, Pulmonary arterial hypertension, risvodetinib

Inhibikase Therapeutics, risvodetinib, Parkinson’s disease, Phase II trial, clinical failure, drug development, pulmonary arterial hypertension (PAH), IkT-001Pro